# Abbott Laboratories (ABT)

> Source: Nexqual · https://nexqual.com/ABT · data as of 2026-10-22 20:02 UTC · cite as "Nexqual, Abbott Laboratories (ABT), nexqual.com/ABT" · informational, not investment advice.

**Price:** USD 102.51 (+1.99% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 100.51 · day 99.95–102.9 · 52w 81.97–132.03 · market cap $177B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $46.6B, net income $5.42B (11.6% margin), free cash flow $7.82B (SEC filings).
- Valuation: P/E 32.7x (avg 27.3x at the last 3 fiscal year-ends), EV/EBITDA 23.0x, net debt $27.0B.
- 7 of 80 tracked superinvestors hold ABT (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 1 new, 2 added, 2 reduced, 2 unchanged.
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $46.9M; 3 not under a Rule 10b5-1 plan ($46.9M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $1.3M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.96 on a 1–5 scale) (28 analysts), mean target USD 118.6 (range 103–130).
- Total return with dividends: 1Y -16.9% vs S&P 500 +14.9%; 5Y -10.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 1.64, revenue estimate $13.2B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B | $46.6B |
| Gross profit | $24.5B | $24.5B | $22.1B | $23.2B | $25.0B | — |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | $7.35B |
| Net income | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B | $5.42B |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | — |
| Free cash flow | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B | $7.82B |
| Gross margin | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | — |
| Operating margin | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% | 15.8% |
| Net margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | 11.6% |
| Revenue growth | +24.5% | +1.3% | -8.1% | +4.6% | +5.7% | — |
| Cash + short-term investments | $10.2B | $10.2B | $7.28B | $7.97B | $8.94B | — |
| Total debt | $18.1B | $16.8B | $14.7B | $14.1B | $12.9B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 32.7x · P/S 3.8x · EV/EBITDA 23.0x · EV/Sales 4.4x · P/FCF 22.7x · P/B 3.5x · FCF yield 4.41% · Earnings yield 3.06% · Dividend yield (paid, TTM) 2.40% · Buyback yield (TTM) 1.03% · Net debt $27.0B · EV $204B
P/E at fiscal year-ends: Dec 2025 33.6x, Dec 2024 14.8x, Dec 2023 33.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
7 of 80 tracked investors hold ABT (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Mason Hawkins | Southeastern Asset Management | 3.98% | $76.3M | New position | Q2 2026 |
| Jensen Investment Management |  | 1.95% | $80.3M | Reduced -40.4% | Q2 2026 |
| Mairs & Power | Mairs & Power Funds | 0.61% | $66.2M | Added +1.1% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.43% | $5.2M | Added +11.7% | Q3 2026 |
| Thomas Russo | Gardner Russo & Quinn | 0.01% | $1.0M | Unchanged | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $1.6M | Unchanged | Q2 2026 |
| Polen Capital | Polen Capital Management | <0.01% | $286K | Reduced -79.1% | Q2 2026 |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | McCoy John A. Jr. | VICE PRESIDENT AND CONTROLLER | 27 | $3K | 0.1% | No | Too little history (no open-market trades in 2023) |
| 2026-08-25 | Ford Robert B | CHAIRMAN AND CEO | 398,832 | $46.2M | 43.3% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | 5,850 | $643K | 7.6% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $1.3M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-07 | Stratton John G | Director | 2,000 | $174K | 86.82 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-27 | Starks Daniel J | Director | 10,000 | $927K | 92.65 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-04-23 | Boudreau Philip P | EVP AND CFO | 2,200 | $201K | 91.5 | Too little history (no open-market trades in 2024) |

## Analysts
Consensus Buy (mean 1.96 on a 1–5 scale), 28 analysts; mean target USD 118.6 (low 103, high 130).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Citigroup | Target lowered | Buy | $125 → $122 |
| 2026-10-22 | RBC Capital | Target lowered | Outperform | $130 → $125 |
| 2026-10-22 | Wells Fargo | Target raised | Overweight | $112 → $119 |
| 2026-10-22 | JP Morgan | Target lowered | Overweight | $120 → $118 |
| 2026-10-22 | TD Cowen | Target lowered | Buy | $135 → $118 |
| 2026-10-22 | Baird | Target raised | Outperform | $121 → $123 |
| 2026-10-22 | BTIG | Target lowered | Buy | $134 → $125 |
| 2026-10-16 | TD Cowen | Reiterated | Buy | $135 |
| 2026-10-07 | Barclays | Initiated | Overweight | $120 |
| 2026-10-02 | Rothschild & Co | Upgrade | Neutral → Buy | $119 → $127 |
| 2026-09-08 | TD Cowen | Reiterated | Buy | $135 |
| 2026-08-25 | TD Cowen | Target raised | Buy | $115 → $135 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -16.9% | -10.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -16.9% | -2.2% |
| Volatility (annualized) | 27.4% | 23.1% |
| Max drawdown | -36.1% (Nov 2025→May 2026) | -37.4% (Feb 2025→May 2026) |

## Peers (Medical Devices)
MDT (Medtronic plc.) USD 96.59 +3.83% · SYK (Stryker Corporation) USD 307.08 +3.19% · BSX (Boston Scientific Corporation) USD 46.01 +3.37% · EW (Edwards Lifesciences Corporatio) USD 90.09 +1.91% · GEHC (GE HealthCare Technologies Inc.) USD 71.42 +3.49% · DXCM (DexCom, Inc.) USD 78.32 -2.42%

## More
Full page: https://nexqual.com/ABT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name ABT in their own reports (relationship from ABT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | MATERIALISE NV (MTLS) | 20-F 2026-04-23 | "In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Enco…" |
| partner | 20/20 Biolabs, Inc. (AIDX) | 10-K 2026-03-31 | "September 29, 2022, the Company entered into a lease agreement with Abbott Laboratories, Inc. for laboratory equipment (analyzer)." |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Medical Devices | $5.85B | 46.5% | +9.0% | $1.97B | 33.6% |
| Diagnostic Products | $3.09B | 24.6% | +42.3% | $499.0M | 16.1% |
| Nutritional Products | $2.14B | 17.0% | -3.1% | $368.0M | 17.2% |
| Established Pharmaceuticals | $1.50B | 11.9% | +8.4% | $382.0M | 25.5% |
| Total revenue | $12.59B | 100% | — | $3.22B | 25.6% |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| International | $7.38B | 58.6% | +7.4% |
| United States | $5.22B | 41.4% | +22.0% |
| Total revenue | $12.59B | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $1.64 | $1.64 | +0.1% | $13.23B | 23 |
| Next quarter (ends 2027-03-31) | $1.24 | $1.29 | -4.1% | $12.61B | 18 |
| Current fiscal year (ends 2026-12-31) | $5.52 | $5.51 | +0.1% | $49.96B | 27 |
| Next fiscal year (ends 2027-12-31) | $5.95 | $6.06 | -1.8% | $53.63B | 27 |